Prognosis and Follow‐Up Recommendations for Subcutaneous and Dermal Leiomyosarcoma: Local Recurrence, Metastasis, and Overall Survival in a Danish Nationwide Cohort of 661 Patients
Journal of Surgical Oncology · 2025-11 · 132 (6) · 1076-1085
DOI: 10.1002/jso.70095 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, online erschienen am 18.09.2025. Verfasst von Kiya Abebe und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic Surgery and Burns Treatment, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Leiomyosarcoma, Neoplasm Recurrence, Local, Skin Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This study was funded by the Research Fund of Copenhagen University Hospital Rigshospitalet and the Danish Medical Society..
Abstract (Originalsprache)
Background and Objectives The prognostic differences between subcutaneous leiomyosarcoma and dermal leiomyosarcoma are not well defined due to limited cohort sizes and insufficient follow‐up in prior studies. This study aimed to investigate the clinicopathological features of subcutaneous and dermal leiomyosarcoma and estimate their 10‐year rates of metastasis, local recurrence, and overall survival. Additionally, we propose standardized follow‐up recommendations.
Methods
All patients diagnosed with cutaneous leiomyosarcoma in Denmark from 1980 to 2022 were included. The prognosis was estimated using age‐ and sex‐standardized stratified cause‐specific Cox‐regression with all‐cause mortality as competing risk.
Results
We included 196 patients with subcutaneous leiomyosarcoma and 465 with dermal leiomyosarcoma. The 10‐year local recurrence rate was similar in patients with subcutaneous leiomyosarcoma (15%) and dermal leiomyosarcoma (11%, p = 0.13). However, patients with subcutaneous leiomyosarcoma had a significantly higher 10‐year risk of metastasis (25%), primarily observed in grade 2 and 3 tumors, compared with dermal leiomyosarcoma (2.7%), p < 0.001, and a lower 10‐year‐overall survival (56% vs. 64%), p = 0.02.
Conclusions
Grade 2 and 3 subcutaneous leiomyosarcoma should be classified as a high‐risk sarcoma with a substantial risk of metastasis and poor overall survival, necessitating follow‐up that includes both clinical examinations and PET/CT or CT of the thorax for 5 years to detect both locoregional and distant metastases. Dermal leiomyosarcoma should be considered a low‐risk sarcoma due to its low risk of metastasis and moderate risk of local recurrence, suggesting that the follow‐up can focus on clinical examinations for 4 years as the 10‐year risk of local recurrence is < 1% after this time point.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Plastic Surgery and Burns Treatment, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Department of Plastic Surgery, Odense University Hospital, Odense, Denmark.
- Department of Orthopedic Surgery, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark.
- Department of Pathology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Department of Immunology and Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
ORCID-Profile: Mathias Ørholt, Michael M Petersen
Förderung
- This study was funded by the Research Fund of Copenhagen University Hospital Rigshospitalet and the Danish Medical Society.
Zitieren
APA
Abebe, K., Ørholt, M., Bak, E. E. F., Larsen, A., Wagenblast, A. L., Schmidt, G., Jensen, D. H., Petersen, M. M., Loya, A. C., Daugaard, S., Herly, M., Hornick, J. L., Mentzel, T., & Vester-Glowinski, P. (2025). Prognosis and Follow‐Up Recommendations for Subcutaneous and Dermal Leiomyosarcoma: Local Recurrence, Metastasis, and Overall Survival in a Danish Nationwide Cohort of 661 Patients. Journal of Surgical Oncology, 132(6), 1076-1085. https://doi.org/10.1002/jso.70095
Vancouver
Abebe K, Ørholt M, Bak EEF, Larsen A, Wagenblast AL, Schmidt G, et al. Prognosis and Follow‐Up Recommendations for Subcutaneous and Dermal Leiomyosarcoma: Local Recurrence, Metastasis, and Overall Survival in a Danish Nationwide Cohort of 661 Patients. Journal of Surgical Oncology. 2025;132(6):1076-1085. doi:10.1002/jso.70095
BibTeX
@article{Abebe2025,
author = {Abebe, Kiya and Ørholt, Mathias and Bak, Erik E F and Larsen, Andreas and Wagenblast, Anne Lene and Schmidt, Grethe and Jensen, David Hebbelstrup and Petersen, Michael M and Loya, Anand C and Daugaard, Søren and Herly, Mikkel and Hornick, Jason L and Mentzel, Thomas and Vester-Glowinski, Peter},
title = {Prognosis and Follow‐Up Recommendations for Subcutaneous and Dermal Leiomyosarcoma: Local Recurrence, Metastasis, and Overall Survival in a Danish Nationwide Cohort of 661 Patients},
journal = {Journal of Surgical Oncology},
year = {2025},
volume = {132},
number = {6},
pages = {1076--1085},
doi = {10.1002/jso.70095}
}
EUVIMED